BioAlliance Pharma: New agreement signed for the distribution of Loramyc® in Iran with Shafayab Gostar
October 18 2012 - 12:04PM
Business Wire
Regulatory News:
BioAlliance Pharma SA (Euronext Paris - BIO), an innovative
Company dedicated to the development of orphan oncology products
and to supportive care products, announces the signature of an
agreement* with the Company Shafayab Gostar to distribute Loramyc®
in Iran (miconazole Lauriad™ mucoadhesive buccal tablet for the
treatment of oropharyngeal candidiasis in immunocompromised
patients).
Under this agreement, Shafayab Gostar is granted the right to
import, promote and market Loramyc® in the Iranian territory once
the registration procedures with the local authorities are
completed. BioAlliance Pharma will remain the Marketing
Authorization Holder of the product.
“This agreement marks the expansion of Loramyc®’s
commercialization worldwide, and especially to emergent markets. We
are delighted to collaborate with the Company Shafayab Gostar, a
key player in the Iranian distribution market,” declares Judith
Greciet, CEO of BioAlliance Pharma.
“With Loramyc® we are adding an innovative product to our
portfolio that meets a medical need in a market where some 180,000
new cancer cases are diagnosed every year. Loramyc® provides a new
therapeutic solution to patients suffering from oropharyngeal
candidiasis, improves their care, particularly for patients at
risk, and their quality of life,” comments A. Sobhanian, CEO of
Shafayab Gostar.
* This agreement was concluded through the Company Cytis AG.
About Shafayab Gostar
Shafayab Gostar was established in 2001 and it represents
Novartis, Bayer Schering, Boehringer Ingelheim, Eli Lilly, Hospira,
Novo Nordisk, Nutricia, Actavis, OctaPharma, IBSA, Desitin and
Convatec in Iran.
About Cytis AG
Cytis AG is specialized in the commercialization and the
promotion of drugs, medical devices and diagnostic products,
especially in the Middle East.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus
on resistance targeting and orphan products, BioAlliance conceives
and develops innovative products, for specialty markets especially
in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in
2005, BioAlliance Pharma’s ambition is to become a leading player
in these fields by coupling innovation to patient needs. The
company’s teams have the key competencies required to identify,
develop and register drugs in Europe and the USA.
BioAlliance Pharma has developed an advanced product
portfolio:
Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised
patients): Registered in 28 countries (EU, US, Korea)
Sitavir®/Sitavig® (Acyclovir LauriadTM) (labialis herpes):
Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary
Phase I results
Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase
III on going
Validive® (Clonidine LauriadTM) (mucositis): Phase II on
going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at
www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of
BioAlliance Pharma SA to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. BioAlliance Pharma SA is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For a discussion of risks and uncertainties which could cause
actual results, financial condition, performance or achievements of
BioAlliance Pharma SA to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2011 Reference Document filed
with the AMF on April 24, 2012, which is available on the AMF
website (http://www.amf-france.org) or on BioAlliance Pharma SA's
website (http://www.bioalliancepharma.com).
Biotest (TG:BIO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biotest (TG:BIO)
Historical Stock Chart
From Oct 2023 to Oct 2024